Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.6252W HIGH $6.25
Volume
98.55 K
Value Traded
4.81 M
Short % Float
1.52%
-9.75%Week
-17.87%1 Month
-6.35%3 Month
-60.09%6 Month
-98.45%5 Year
-99.97%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
5.57 M
EPS (TTM)
-0.92
P/E Ratio
-
Ent. Value
-3.14 M
Total Shares
6.59 M
Float Shares
5.56 M
Insiders
15.70%
Institutions
5.66%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
CELZ Catalyst Timeline
Dated clinical, regulatory and corporate events for Creative Medical Technology Holdings, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Creative Medical Technology Holdings, Inc.
187Total events
18Upcoming
33Tier-1 (high impact)
2016 to 2026Coverage
Upcoming catalysts 2
Event history 50
●Composition Patent FiledUltrasomeIP / Competition
New U.S. provisional patent application filed expanding Ultrasome IP protection
▲Enrollment CompleteCELZ-201Trial
Completed enrollment and treatment across entire ADAPT trial including opioid cohort
chronic lower back pain associated with degenerative disc diseasesource ↗
▲Quarterly UpdateCELZ-201Corporate
ADAPT transitions to follow-up, data maturation, and regulatory planning
chronic lower back pain associated with degenerative disc diseasesource ↗
▲Interim AnalysisCELZ-201Trial
Positive interim 180-day follow-up data reported
chronic lower back pain associated with degenerative disc diseasesource ↗
▲DSMB ReviewCELZ-201Trial
Positive DSMB review confirmed favorable safety profile
chronic lower back pain associated with degenerative disc diseasesource ↗
▲Patent GrantedIP / Competition
Notice of Allowance for U.S. patent application covering exosome-based immunotherapy for Type 1 diabetes
Type 1 diabetessource ↗
◆Enrollment CompleteCELZ-201Trial
Expansion cohort enrollment completion expected
chronic lower back pain associated with degenerative disc diseasesource ↗
▼Equity OfferingCorporate
Agreements for exercise of warrants for $4.5 million gross proceeds
▲IND ClearanceCELZ-201IND
FDA clearance of ADAPT trial expansion cohort
chronic lower back pain associated with degenerative disc diseasesource ↗
▲Enrollment UpdateCELZ-201Trial
Expansion cohort enrollment >85%
chronic lower back pain associated with degenerative disc diseasesource ↗
▲Interim AnalysisCELZ-201Trial
Positive interim 180-day data
chronic lower back pain associated with degenerative disc diseasesource ↗
▲DSMB ReviewCELZ-201Trial
Favorable DSMB review
chronic lower back pain associated with degenerative disc diseasesource ↗
▲Other Regulator MilestoneEx-US Regulatory
Regulatory approval to proceed with BioDefense Burn Pit Initiative
burn pit and toxic exposuresource ↗
▲Enrollment MilestoneTrial
Nationwide virtual participant onboarding and data collection phase initiated
burn pit and toxic exposuresource ↗
▲IND ClearanceCELZ-201IND
FDA cleared expansion of ADAPT trial to enroll additional cohort
chronic lower back pain associated with degenerative disc diseasesource ↗
▲Enrollment UpdateCELZ-201Trial
Expanded ADAPT cohort more than 85% enrolled
chronic lower back pain associated with degenerative disc diseasesource ↗
▲Trial InitiationTrial
Project PHOENIX advanced into nationwide AI-enabled virtual data collection phase
toxic burn pit exposuresource ↗
▲Enrollment MilestoneTrial
Project PHOENIX advanced into nationwide AI-enabled virtual data collection phase targeting 1,000 veterans
toxic burn pit exposuresource ↗
▲FDA Feedback ReceivedCELZ-201FDA Meeting
FDA cleared expansion of ADAPT trial to enroll opioid cohort
chronic lower back pain associated with degenerative disc diseasesource ↗
▲Topline ReadoutUltrasomeClinical Data
Ultrasome pilot study topline results: 93% response rate, primary endpoint met
osteoarthritis of the kneesource ↗
▲Primary Endpoint MetUltrasomeClinical Data
Ultrasome pilot study primary endpoint met
osteoarthritis of the kneesource ↗
◆Topline ReadoutCELZ-201Clinical Data
Topline data expected in Q2 2026
chronic lower back pain associated with degenerative disc diseasesource ↗
▲Topline ReadoutUltrasomeClinical Data
Pilot study reported ~93% of knee osteoarthritis participants with clinically meaningful improvements in mobility and pain
knee osteoarthritissource ↗
▲Primary Endpoint MetUltrasomeClinical Data
Breakthrough pilot results for Ultrasome: 93% patients achieved clinically meaningful improvements
osteoarthritis of the kneesource ↗
▲Timing GuidanceUltrasomePresentation
Pilot study in knee osteoarthritis reported ~93% clinically meaningful improvements in mobility and pain
knee osteoarthritissource ↗
▲Interim AnalysisCELZ-201Trial
Positive interim 180-day follow-up data from ADAPT trial
chronic lower back pain associated with degenerative disc diseasesource ↗
▲Other Regulator MilestoneEx-US Regulatory
BioDefense Burn Pit Initiative receives regulatory approval to proceed
burn pit exposuresource ↗
◆Topline ReadoutCELZ-201Clinical Data
Topline data readout expected in Q1 2026
chronic lower back pain associated with degenerative disc diseasesource ↗
▲Interim AnalysisCELZ-201Trial
Positive interim blinded 180-day data from ADAPT trial
chronic lower back pain associated with degenerative disc diseasesource ↗
▲Other Regulator MilestoneEx-US Regulatory
BioDefense Inc. Burn Pit Initiative received regulatory approval to proceed nationally
toxic burn pit exposuresource ↗
▲DSMB ReviewCELZ-201Trial
Positive DSMB review confirmed favorable safety profile
chronic lower back pain associated with degenerative disc diseasesource ↗
▲Interim AnalysisCELZ-201Trial
Positive interim 180-day follow-up data announced
chronic lower back pain associated with degenerative disc diseasesource ↗
▲Enrollment CompleteCELZ-201Trial
Completed enrollment in ADAPT trial for CELZ-201
chronic lower back pain associated with degenerative disc diseasesource ↗
▲DSMB ReviewCELZ-201Trial
Positive DSMB safety review for CELZ-201
chronic lower back pain associated with degenerative disc diseasesource ↗
▲Other Regulator MilestoneCELZ-201Ex-US Regulatory
WHO approved INN 'olastrocel' for CELZ-201
▲Enrollment CompleteCELZ-201Trial
Original ADAPT cohort enrollment completed
chronic lower back pain associated with degenerative disc diseasesource ↗
▲Partnership / LicenseCorporate
Partnership with Greenstone Biosciences for AI and iPSC development
toxic burn pit exposuresource ↗
▼Equity OfferingCorporate
Agreements for exercise of warrants for $4.2 million gross proceeds
▲Patent GrantedImmCelzIP / Competition
U.S. Patent 12385011B2 for Heart Failure granted
Heart Failure / Post Infarct Pathological Remodelingsource ↗
▲Fast Track DesignationCELZ-201-DDTDesignation
FDA grants Fast Track designation for CELZ-201-DDT
degenerative disc disease (DDD)source ↗
◆Enrollment CompleteCELZ-201-DDTTrial
Final enrollment nearing in FDA-cleared clinical trial
degenerative disc disease (DDD)source ↗
▲Patent GrantedImmCelzIP / Competition
Notice of Allowance for U.S. patent application for prevention/treatment of Type 1 Diabetes using ImmCelz
Type 1 Diabetessource ↗
▲Patent GrantedImmCelzIP / Competition
Notice of Allowance for ImmCelz patent for heart failure treatment
Heart Failure and/or Post Infarct Pathological Remodelingsource ↗
▲Patent GrantedIP / Competition
U.S. patent granted for ImmCelz coverage in Type 1 Diabetes
Type 1 Diabetessource ↗
▲Other Regulator MilestoneCELZ-101Ex-US Regulatory
WHO publishes proposed INN 'etaroleucel' for CELZ-101 in Proposed INN List 134
Type 1 diabetes in the context of pancreatic islet transplantationsource ↗
▲IND ClearanceCELZ-201-DDTIND
FDA clearance for expanded dose escalation in Phase 1/2 trial of CELZ-201-DDT
chronic lower back pain caused by degenerative disc diseasesource ↗
▲Interim AnalysisCELZ-201-DDTTrial
Interim blinded data showing statistically significant pain reduction and improved mobility
chronic lower back pain caused by degenerative disc diseasesource ↗
▲Enrollment MilestoneCELZ-201-DDTTrial
Half of trial enrollment completed
chronic lower back pain caused by degenerative disc diseasesource ↗
▼Equity OfferingCorporate
Agreements for exercise of warrants for $3.7 million gross proceeds
Past FDA Catalysts and PDUFA Decisions
How CELZ actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D36 / 100
Pipeline Score
$3M
Pipeline Value
Overvalued
Valuation Signal
2
Drugs Scored
0.6x
rNPV / MCap
Top 50%
Micro Cap(rank 329 of 658)
Percentile Rank
Creative Medical Technology Holdings, Inc. faces pipeline headwinds (36/100), with $278M risk-adjusted pipeline value, led by CELZ-201 in Type 1 Diabetes (Phase 1), across $73B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CELZ-201 Monoclonal antibodyNCT05626712 | Type 1 Diabetes | Phase 1 | RECRUITING | 18 | Jan 31, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every CELZ program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| CELZ-201 (Olastrocel) Fast TrackRMAT | chronic lower back pain | 2026-06-22 | statistically significant, clinically meaningful improvements in functional disability (ODI%) and painRead More | Creative Medical Technology Holdings Expands ADAPT Trial Under New FDA Clearance and Rapidly Advances Toward Phase 3 Planning for Olastrocel in Chronic Lower Back PainRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Finger Michael H.Director | Sell | -750 351 held | $5.75 | 02/19/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in CELZ
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in CELZ for Q2 2026. | ||||
CELZ Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CELZ ranks across every disease it competes in
Competitive Position is a premium feature
See how CELZ ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCELZ News
CELZ▲ +6.8%on this news· ran to +18% by day 1
Creative Medical Technology Holdings, Inc. Expands Ultrasome™ Intellectual Property Portfolio with New U.S. Provisional Patent Filing
Creative Medical Technology Holdings, Inc. has filed a new U.S. provisional patent application to enhance its Ultrasome™ regenerative medicine platform. This filing aims to protect various aspects of the platform, including product composition and therapeutic applications. The company continues to explore Ultrasome's potential beyond osteoarthritis, emphasizing the importance of intellectual property in its development strategy.
Read more →CELZ▲ +14.3%on this news
Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning
Creative Medical Technology Holdings has successfully completed enrollment and treatment in its FDA-cleared ADAPT trial for CELZ-201 (Olastrocel), which targets chronic lower back pain. The trial's positive safety and efficacy signals support further development, including RMAT evaluation and Phase 3 planning. The company anticipates reduced costs as it transitions to follow-up and regulatory planning.
Read more →CELZ▲ +71.9%on this news· ran to +112% by day 1
Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms
Creative Medical Technology Holdings, Inc. announced it received a Notice of Allowance for a U.S. patent on exosome-based immunotherapy targeting Type 1 diabetes. This patent will enhance their MyeloCelz™ platform, which aims to induce immune tolerance and protect insulin-producing cells. The company continues to expand its intellectual property portfolio, which now includes around 60 patents and applications.
Read more →CELZ▼ -12.4%on this news· ran to -25% by day 3
Creative Medical Technology Holdings Issues Mid-Year Update
Creative Medical Technology Holdings has provided a mid-year update highlighting its progress in clinical programs for chronic lower back pain and osteoarthritis. The company is advancing Olastrocel towards Phase 3 readiness and has reported positive interim data from the ADAPT trial. Additionally, Ultrasome™ has shown promising results, and the company is expanding its biodefense initiatives. Overall, Creative Medical is focused on disciplined capital allocation and strategic partnerships.
Read more →CELZ▼ -48.2%on this news· ran to -59% by day 3shared move
Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.5 Million Gross Proceeds
Creative Medical Technology Holdings, Inc. has announced agreements for the immediate exercise of warrants, expected to generate approximately $4.5 million in gross proceeds. The warrants allow for the purchase of up to 2,790,340 shares at a reduced price of $1.60 each. The proceeds will be used for working capital and corporate purposes, with a transaction closing date set for June 30, 2026.
Read more →CELZ▼ -13.5%on this news
Creative Medical Technology Holdings Expands ADAPT Trial Under New FDA Clearance and Rapidly Advances Toward Phase 3 Planning for Olastrocel in Chronic Lower Back Pain
Creative Medical Technology Holdings has received FDA clearance to expand its ADAPT trial for CELZ-201 (Olastrocel) in chronic lower back pain patients. The trial will enroll an additional 15 patients using less than 90 mg of morphine equivalents per day. The expansion follows positive interim results from the original cohort, which demonstrated significant improvements in pain and functional disability. The company is preparing for Phase 3 discussions with the FDA, aiming to address the urgent need for non-opioid treatment options.
Read more →CELZ▼ -6.3%on this news· ran to -19% by day 3shared move
Creative Medical Technology Holdings, Inc. Advances Project PHOENIX into Nationwide AI Driven Virtual Data Collection Phase for U.S. Veterans Exposed to Burn Pits and Toxic Hazards
Creative Medical Technology Holdings, Inc. has advanced Project PHOENIX into a nationwide phase focused on AI-driven virtual data collection for veterans exposed to burn pits and toxic hazards. This initiative aims to onboard at least 1,000 veterans, utilizing a mobile app for data collection and field-capable logistics. The project seeks to create a comprehensive dataset to identify biomarkers and therapeutic targets related to toxic exposure.
Read more →CELZCreative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies
Creative Medical Technology Holdings, Inc. reported positive results from its pilot study of Ultrasome™, a cell-free regenerative therapy for knee osteoarthritis. The study achieved a 93% response rate, indicating significant improvements in patient mobility and pain reduction. The therapy is derived from the GMP-manufactured CELZ-201 and aims to expand treatment options for osteoarthritis, a condition affecting over 30 million adults in the U.S.
Read more →CELZCreative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline
Creative Medical Technology Holdings has achieved its second International Nonproprietary Name (INN) milestone with the WHO for its autologous T-cell immunotherapy, CELZ-101, now proposed as 'etaroleucel'. This follows the earlier INN recognition of 'olastrocel' for CELZ-201, indicating strong regulatory progress in its expanding cell therapy pipeline aimed at high unmet medical needs.
Read more →CELZ▼ -11.2%on this news
Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain
Creative Medical Technology Holdings announced positive interim results from its ADAPT trial for CELZ-201 (Olastrocel), a cell therapy for chronic lower back pain. The trial showed significant improvements in functional disability and pain, confirming its efficacy and safety. The company is now focusing on regulatory engagement and commercialization planning.
Read more →CELZ▲ +9.3%on this news
Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative
Creative Medical Technology Holdings has received regulatory approval for its BioDefense Inc. Burn Pit Initiative, enabling expanded research into the health effects of burn pit exposure among U.S. veterans. The initiative will utilize existing partnerships and infrastructure, eliminating the need for additional fundraising. This approval is seen as a pivotal moment for the company as it aims to develop AI-driven regenerative solutions to support veterans' health. The program is expected to enhance national biodefense capabilities.
Read more →CELZCreative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point
Creative Medical Technology Holdings, Inc. has completed patient enrollment in its FDA-cleared ADAPT trial for CELZ-201 (Olastrocel), a cell therapy for chronic lower back pain. This milestone follows a positive safety review, indicating a favorable safety profile for the therapy. The company is now focused on data analysis and follow-up, aiming to generate impactful clinical results.
Read more →CELZCreative Medical Technology Holdings Announces World Health Organization Approval of “olastrocel” as INN for Lead Allogeneic Cell Therapy CELZ-201
Creative Medical Technology Holdings has received approval from the World Health Organization for the name 'olastrocel' as the International Non-Proprietary Name for its lead allogeneic cell therapy, CELZ-201. This milestone is significant for regulatory positioning and global market clarity. The company aims to target major therapeutic areas with unmet medical needs, including chronic lower back pain and diabetes.
Read more →CELZ▼ -13%on this news· ran to -24% by day 3
Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits
Creative Medical Technology Holdings, Inc. has launched the BioDefense Inc. Veterans Initiative, aimed at addressing the long-term effects of burn pit exposure among U.S. veterans. This innovative program combines proprietary regenerative technologies with AI analytics to develop precision therapies. The initiative is supported by a partnership with Greenstone Biosciences, enhancing its capabilities in biodefense and veteran healthcare.
Read more →CELZ▼ -32.7%on this news· ran to -46% by day 3shared move
Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceeds
Creative Medical Technology Holdings, Inc. has announced agreements for the immediate exercise of warrants, which will generate approximately $4.2 million in gross proceeds. The company will issue new unregistered warrants as part of the transaction, which will be exercisable for five years following shareholder approval. The funds will be used for working capital and general corporate purposes.
Read more →CELZ▲ +5.4%on this news· ran to -33% by day 3shared move
Creative Medical Technology Holdings Issues Letter to Shareholders
Creative Medical Technology Holdings has issued a letter to shareholders highlighting significant advancements in 2025. The company is transitioning from proof-of-concept to clinical trials, focusing on regenerative stem cell therapies. With a robust intellectual property portfolio and integration of AI, Creative Medical aims to redefine regenerative medicine and enhance shareholder value.
Read more →CELZCreative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs
Creative Medical Technology Holdings congratulated the 2025 Nobel Laureates for their work on regulatory T cells, which has influenced modern immunology. The company also announced the receipt of two U.S. patents for its ImmCelz™ platform, aimed at treating Type 1 diabetes and heart failure. CEO Timothy Warbington emphasized the potential of Tregs in regenerative immunotherapy.
Read more →About Creative Medical Technology Holdings, Inc.
Headquarters211 E. OSBORN RD., PHOENIX, AZ, 85012
BIOPHARMAWATCH ELITE PLUS
Trade the next CELZ catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime